Company logo

PALI - Palisade Bio, Inc.

NASDAQ -> Healthcare -> Biotechnology
Carlsbad, United States
Type: Equity

PALI price evolution
PALI
(in millions $) 30 Oct 2023 30 Jul 2023 1 May 2023 31 Jan 2023
Current assets
Cash
Short term investments
Net receivables $0.14 $0.04 $0.33 $1.44
Inventory
Total current assets $16.27 $17.41 $14.31 $14.73
Long term investments
Property, plant & equipment $0.23 $0.26 $0.28 $0.31
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $17.07 $18.29 $15.26 $15.76
Current liabilities
Accounts payable $0.95 $0.92 $0.71 $1.76
Deferred revenue
Short long term debt
Total current liabilities $2.65 $2.33 $1.31 $3.01
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $2.99 $2.49 $1.51 $3.28
Shareholders' equity
Retained earnings -$118.54 -$114.92 -$111.53 -$109.19
Other shareholder equity
Total shareholder equity
(in millions $) 31 Jan 2023 31 Jan 2022 31 Jan 2021 31 Jan 2020
Current assets
Cash
Short term investments
Net receivables $1.44 $0.15 $0.12 $0.02
Inventory
Total current assets $14.73 $12.37 $12.88 $5.65
Long term investments
Property, plant & equipment $0.31 $0.11 $0.01 $0.04
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $15.76 $12.51 $13.05 $6.58
Current liabilities
Accounts payable $1.76 $1.32 $0.65 $0.82
Deferred revenue
Short long term debt
Total current liabilities $3.01 $2.5 $3.21 $1.22
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $3.28 $5.15 $3.28 $1.46
Shareholders' equity
Retained earnings -$109.19 -$94.64 -$238.24 -$221.98
Other shareholder equity -$0.01
Total shareholder equity
(in millions $) 30 Oct 2022 29 Jul 2022 30 Apr 2022 31 Jan 2022
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $4 $3.57 $3.89 $4.03
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense $0.38 $1.22 $0.79 $5.09
Net income
Net income -$3.99 -$2.34 -$4.21 $1.07
Income (for common shares)
(in millions $) 31 Jan 2022 31 Jan 2021 31 Jan 2020 31 Jan 2019
Revenue
Total revenue $0.01 $0.02 $0.26
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $11.74 $10.69 $8.65 $8.52
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense $20.64 $0.03 $0.56 $3.34
Net income
Net income -$26.62 -$16.27 -$8.35 -$4.92
Income (for common shares)
(in millions $) 30 Oct 2022 29 Jul 2022 30 Apr 2022 31 Jan 2022
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.05
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $13.54 $1.5 -$0.09 $24.61
Effect of exchange rate
Change in cash and equivalents $3.49 -$5.52 -$3.85 $9.78
(in millions $) 31 Jan 2022 31 Jan 2021 31 Jan 2020 31 Jan 2019
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.05 $5
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $24.61 $14.47 $6.59 $1.81
Effect of exchange rate -$0.01 -$0.01
Change in cash and equivalents $9.78 $5.44 -$0.68 -$0.89
Fundamentals
Market cap $3.68M
Enterprise value N/A
Shares outstanding 9.21M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income -$9.47M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -0.39
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$1.03
ROA -57.04%
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 6.14
Quick ratio N/A